Anavex Life Sciences Corp., of New York, reported data from a preclinical study of ANAVEX2-73 showing the drug accelerates the maturation of oligodendrocyte precursor cells (OPCs) to oligodendrocytes (OLs), potentially leading to remyelination in MS patients.